Revenue from customers In the three months ending September 30, 2021 and 2020, the company has recognized customer revenue of $0 and $100,000, respectively. The decrease in revenue from customers was due to the decrease in revenue from licensing and royalties during the current period.

The table below shows a summary of the net cash flow activities for each of the following periods:

Catalog Our forecasts of working capital requirements are based on assumptions that may prove to be incorrect, and we may use all available capital resources faster than expected. Due to the numerous risks and uncertainties associated with the research, development and commercialization of pharmaceutical products, we cannot estimate the exact amount of our working capital requirements. Our future funding needs will depend on many factors, including but not limited to:

Amend the company’s effective date to the reporting period beginning after December 15, 2022. The company will adopt the ASU, effective from July 1, 2023.

© Edgar Online, a glimpse of the source